[2]Grant MJ, Aredo JV, Starrett JH, Stockhammer P, et,al. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clin Cancer Res. 2023 Jun 1;29(11):2123-213...
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clin Cancer Res. 2023 Jun 1;29(11):2123-2130. doi: 10.1158/1078-0432.CCR-22-3497. PMID: 36913537.往期推荐 ...
8. Grant MJ, Aredo JV, Starrett JH, et al. Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations. Clin Cancer Res. 2023 Mar 13:CCR-22-3497. 本材料由阿斯利康提供,仅供医疗卫生专业人士参考 审批编号 CN-114919 过期日期 2023-8-17 ...
"Impact of EGFR Exon 19 Deletion Subtypes on Clinical Outcomes in EGFR-TKI-Treated Advanced Non-Small-Cell Lung Cancer." Lung Cancer (2022). [2]Grant MJ, Aredo JV, Starrett JH, Stockhammer P, et,al. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19...
20.Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019. ...
14. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–640. 15. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018...
[1]. Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017; 376(7): 629-640.[2]. Ramalingam SS, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020; 382(1): 41-50.[3]. ...
9.Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. The Lancet Oncology, 2019, 20(...
9.Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. The Lancet Oncology, 2019, 20(...
英文摘要: OBJECTIVE:To evaluate the economic s of osimertinib versus first-generation EGFR-TKIs in the first-line treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC),and to provide evidence-based reference for medical and healthy decision-making in ...